Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe
Аутори
Skrede, SiljeBogavac-Stanojević, Nataša
Dreesen, Erwin
Nielsen, Elisabet
Zaninotto, Martina
Mulleman, Denis
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The European Cooperation in Science and Technology (COST) action ENOTTA (The European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases) was launched in 2022. To pave the way for harmonization of analytical methods for quantitation of serum levels of therapeutic antibodies in research and clinical settings, ENOTTA recently performed an online survey mapping laboratories in the field. The survey, which contained 30 questions surrounding therapeutic drug monitoring of relevant drugs and anti-drug antibodies, was distributed via the ENOTTA and European Federation of Clinical Chemistry and Laboratory networks. Among 63 respondents across Europe, 45 reported analytical activity, with a range of utilized methods. Future engagement of as many sites as possible will enable comparison of methodologies and facilitate progress in the field.
Кључне речи:
analyses / COST / harmonization / survey / therapeutic antibodiesИзвор:
Basic and Clinical Pharmacology and Toxicology, 2024Издавач:
- John Wiley and Sons Inc
Финансирање / пројекти:
- The European Cooperation inScience and Technology (COST) for funding activitiesenabling design and distribution of the survey throughCOST action CA21147 - European Network on Optimis-ing Treatment with Therapeutic Antibodies in chronicinflammatory diseases (ENOTTA), with Dr Mulleman asprincipal investigator
DOI: 10.1111/bcpt.13983
ISSN: 1742-7835
PubMed: 38278525
WoS: 001149492200001
Scopus: 2-s2.0-85183153994
Институција/група
PharmacyTY - JOUR AU - Skrede, Silje AU - Bogavac-Stanojević, Nataša AU - Dreesen, Erwin AU - Nielsen, Elisabet AU - Zaninotto, Martina AU - Mulleman, Denis PY - 2024 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5532 AB - The European Cooperation in Science and Technology (COST) action ENOTTA (The European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases) was launched in 2022. To pave the way for harmonization of analytical methods for quantitation of serum levels of therapeutic antibodies in research and clinical settings, ENOTTA recently performed an online survey mapping laboratories in the field. The survey, which contained 30 questions surrounding therapeutic drug monitoring of relevant drugs and anti-drug antibodies, was distributed via the ENOTTA and European Federation of Clinical Chemistry and Laboratory networks. Among 63 respondents across Europe, 45 reported analytical activity, with a range of utilized methods. Future engagement of as many sites as possible will enable comparison of methodologies and facilitate progress in the field. PB - John Wiley and Sons Inc T2 - Basic and Clinical Pharmacology and Toxicology T1 - Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe DO - 10.1111/bcpt.13983 ER -
@article{ author = "Skrede, Silje and Bogavac-Stanojević, Nataša and Dreesen, Erwin and Nielsen, Elisabet and Zaninotto, Martina and Mulleman, Denis", year = "2024", abstract = "The European Cooperation in Science and Technology (COST) action ENOTTA (The European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases) was launched in 2022. To pave the way for harmonization of analytical methods for quantitation of serum levels of therapeutic antibodies in research and clinical settings, ENOTTA recently performed an online survey mapping laboratories in the field. The survey, which contained 30 questions surrounding therapeutic drug monitoring of relevant drugs and anti-drug antibodies, was distributed via the ENOTTA and European Federation of Clinical Chemistry and Laboratory networks. Among 63 respondents across Europe, 45 reported analytical activity, with a range of utilized methods. Future engagement of as many sites as possible will enable comparison of methodologies and facilitate progress in the field.", publisher = "John Wiley and Sons Inc", journal = "Basic and Clinical Pharmacology and Toxicology", title = "Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe", doi = "10.1111/bcpt.13983" }
Skrede, S., Bogavac-Stanojević, N., Dreesen, E., Nielsen, E., Zaninotto, M.,& Mulleman, D.. (2024). Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe. in Basic and Clinical Pharmacology and Toxicology John Wiley and Sons Inc.. https://doi.org/10.1111/bcpt.13983
Skrede S, Bogavac-Stanojević N, Dreesen E, Nielsen E, Zaninotto M, Mulleman D. Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe. in Basic and Clinical Pharmacology and Toxicology. 2024;. doi:10.1111/bcpt.13983 .
Skrede, Silje, Bogavac-Stanojević, Nataša, Dreesen, Erwin, Nielsen, Elisabet, Zaninotto, Martina, Mulleman, Denis, "Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe" in Basic and Clinical Pharmacology and Toxicology (2024), https://doi.org/10.1111/bcpt.13983 . .